Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 4 ans
Étude I8S-MC-JUAB : étude de phase 1 visant à évaluer la sécurité du LY3124996, un inhibiteur de la voie de signalisation ERK1/2, administré seul ou en association avec d’autres agents anticancéreux chez des patients ayant un cancer de stade avancé.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, organes… Ce sont les plus fréquents. La majorité des cancers suivent les mêmes étapes mais à des vitesses variables. Les cel...
Country
France
organs
Mélanomes cutanés
,
Pancréas
,
Poumon, type non à petites cellules
,
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 4 ans
Étude KEYNOTE 287 : étude de phase 1b non-randomisée visant à évaluer la sécurité d’emploi et l’efficacité de l’abémaciclib en association au pembrolizumab chez des patients ayant un cancer du poumon non à petites cellules au stade IV ou un cancer du sein positif pour le récepteur hormonal et négative pour HER2. [essai clos aux inclusions]
Le cancer du poumon non à petites cellules est le type de cancer du poumon le plus fréquent, qui représente 85 à 90% de l’ensemble des cancers du poumon. Le cancer du poumon non à petites cellules mét...
Country
France
organs
Poumon, type non à petites cellules
,
Sein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
Comparison of Premixed Insulin Lispro Low Mixture and Mid Mixture Regimens with Separate Basal and Bolus Insulin Injections in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Oral Therapy who Consume Light Breakfast
The primary objective of this study is to test the hypothesis that glycemic control achieved when initiating insulin treatment with insulin lispro mid mix /low mix as a single daily injection either b...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiety Disorder
The primary objective is to assess whether duloxetine 30 to 120 mg once daily is superior to placebo in the treatment of elderly patients (≥65 years old) with Generalized anxiety disorder (GAD).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Effect of Passive Immunization on the Progression of Alzheimer´s Disease: LY2062430 versus Placebo. Efecto de la inmunización pasiva sobre la progresión de la enfermedad de Alzheimer: LY2062430 frente a placebo
The primary objective of this study is to test the hypothesis that intravenous infusion of LY2062430 will slow the decline of AD as compared with placebo, as assessed at 80 weeks after initiation of t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo
The primary objective of this study is to test the hypothesis that LY450139 given orally will slow the decline associated with AD as compared with placebo. This will be evaluated sometime between 64 a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The primary objective is to estimate the progression-free survival (PFS) for the combination of pemetrexed plus cisplatin plus cetuximab followed by optional pemetrexed plus cetuximab maintenance ther...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer
To estimate the time-to-progressive disease for patients who have received LY573636 after two prior treatment regimens of systemic therapy for unresectable, metastatic non-small cell lung cancer (NSCL...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
The primary objective of this study is to assess whether duloxetine hydrochloride 60 to 120 mg once daily (QD) is superior to placebo in the treatment of generalized anxiety disorder (GAD), as defined...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)
The primary objective of the study is to assess the effect of missed doses of atomoxetine and OROS methylphenidate in ADHD patients who are stable on pharmacotherapy based on the patient’s daily behav...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next